Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.


Journal

The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 31 05 2019
revised: 06 06 2019
accepted: 11 06 2019
pubmed: 14 6 2019
medline: 4 12 2019
entrez: 14 6 2019
Statut: ppublish

Résumé

After the publication of an article discussing the methodological options to detect the diversion potential of prescription drugs, this letter presents the multidimensional functioning of the French Addictovigilance System. This system aims at monitoring all substances with abuse potential, relying on a network of experts specialized in clinical and fundamental pharmacology. For more than 25 years, we have created collaborations with partners at the interface with field data related to substance use and the potential related disorders. When relevant depending on the context, these data sources are explored and crossed to analyze the abuse potential of one given substance. This organizational approach is useful to detect early Addictovigilance warning signals and to take appropriate measures. Generalizing such a multidimensional approach outside France appears an appealing option to move towards more effective Addictovigilance systems at the international level.

Identifiants

pubmed: 31194866
pii: 5517077
doi: 10.1093/ijnp/pyz033
pmc: PMC6672683
doi:

Types de publication

Letter Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

528-530

Commentaires et corrections

Type : CommentOn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of CINP.

Références

Br J Clin Pharmacol. 2017 Aug;83(8):1791-1800
pubmed: 28239898
Clin Drug Investig. 2016 Sep;36(9):735-742
pubmed: 27300651
Br J Clin Pharmacol. 2019 Jun;85(6):1260-1269
pubmed: 30737829
Psychopharmacology (Berl). 2019 Jul;236(7):2069-2082
pubmed: 30879119
Eur Addict Res. 2012;18(5):228-45
pubmed: 22572594
Therapie. 2015 Mar-Apr;70(2):113-31
pubmed: 25858567
Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277
pubmed: 30722037
Trends Cardiovasc Med. 2019 Oct;29(7):403-407
pubmed: 30447899
J Am Heart Assoc. 2014 Apr 23;3(2):e000638
pubmed: 24760961
N Engl J Med. 2018 Jul 19;379(3):205-207
pubmed: 29847203

Auteurs

Emilie Jouanjus (E)

CEIP-Addictovigilance, Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Toulouse, France.
French Addictovigilance Network.

Joëlle Micallef (J)

CEIP-Addictovigilance, Service de Pharmacologie Clinique, CHU Timone, Marseille, France.
French Addictovigilance Network.

Michel Mallaret (M)

CEIP-Addictovigilance, Service de Pharmacologie Clinique, CHU Grenoble, Grenoble, France.
French Addictovigilance Network.

Maryse Lapeyre-Mestre (M)

CEIP-Addictovigilance, Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Toulouse, France.
French Addictovigilance Network.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH